One-Third Of Payers Preferred Biosimilars Over Reference Drug in 2017
As biosimilar uptake remains modest, rebate amounts trend upward for medical benefit drugs, according to latest MagellanRx drug trend report.
You may also be interested in...
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
Pfizer's suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any of Pfizer's biosimilar Inflectra is reimbursed, but J&J says Pfizer has failed to show the value of Inflectra.